Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a "real-world" observational study in the United States.

24 Patients newly initiating rivaroxaban, as compared with warfarin, were numerically more likely to experience a major bleeding event but the adjusted differences in major bleeding between rivaroxaban and warfarin did not reach statistical significance.

also in 111,027 other papers